Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy

Ilhan Y., Ucar G., Baser M. N., Guzel H. G., Efil S. C., Demir B., ...Daha Fazla

Expert Opinion on Pharmacotherapy, cilt.25, sa.11, ss.1555-1563, 2024 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 11
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1080/14656566.2024.2391007
  • Dergi Adı: Expert Opinion on Pharmacotherapy
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1555-1563
  • Anahtar Kelimeler: Chemoimmunotherapy, G-CSF, granulocyte-colony stimulating factor, immune check point inhibitors, SCLC, small cell lung cancer
  • Gazi Üniversitesi Adresli: Evet

Özet

Objectives: We aimed to evaluate the efficacy and safety of granulocyte-colony stimulating factor (G-CSF) prophylaxis during chemoimmunotherapy with carboplatin plus etoposide and atezolizumab in extensive-stage small cell lung cancer (ES-SCLC). Methods: This retrospective, multicenter study enrolled ES-SCLC patients receiving carboplatin plus etoposide and atezolizumab, categorized into G-CSF and non-G-CSF groups. Demographic and disease-related data were collected. Response rates, progression-free survival (PFS), overall survival (OS), and toxicity were analyzed. Results: Of 119 patients (median age: 63 years), the overall response rate (ORR) and disease control rate (DCR) were 72.3% and 81.5%, respectively. In the G-CSF group, the ORR was 76.4% compared to 60.0% in the non-G-CSF group (p = 0.33), and the DCR was 85.4% versus 70.0%, respectively (p = 0.46). Median PFS was 8.3 months (95% CI, 6.8–9.8) in the G-CSF group and 6.8 months (95% CI, 6.2–7.5) in the non-G-CSF group (p = 0.24). Median OS was 13.8 months (95% CI, 9.6–18.1) for the G-CSF group and 10.6 months (95% CI, 7.9–13.3) for the non-G-CSF group (p = 0.47). Grade 3 ≥ adverse events were similar between groups (49.4% vs. 33.3%, respectively, p = 0.12). Conclusion: G-CSF prophylaxis can be safely used in ES-SCLC patients undergoing carboplatin plus etoposide and atezolizumab regimen without significantly altering efficacy or increasing toxicity.